Neuroendocrine Cancers (NETs and NECs) are globally increasing in incidence (those newly diagnosed) and prevalence (those living with Neuroendocrine Cancer). However, many may not be diagnosed until liver metastases (spread) has occurred.
Neuroendocrine liver metastases (NELM) can vary in the how they develop and the symptoms they may cause. They may also affect prognosis (life expectancy).
Fortunately, advances in how they are diagnosed and treated have improved outcomes – including both quality of life and life expectancy.
Cloyd et al. “Neuroendocrine liver metastases: a contemporary review of treatment strategies.”
At our recent well attended “Liver Metastases Natter”, we were joined by Mr Thomas Armstrong (Consultant Surgeon and Lead Clinician for the Wessex Neuroendocrine Tumour Group / Southampton Centre of Excellence). Mr Armstrong gave an excellent talk about the ways in which liver metastases are diagnosed and treated – including the factors that may influence choice of treatment.
You can watch the talk below:
Find out more about Secondary Neuroendocrine Cancer here.